ADENOSINE

Post-LOE

adenosine

Teva

ANDAINJECTIONINJECTABLE

Approved

Jul 2008

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ADENOSINE (adenosine) by Teva is mechanism of action adenosine slows conduction time through the a-v node, can interrupt the reentry pathways through the a-v node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (psvt), including psvt associated with wolff-parkinson-white syndrome. Approved for atrial fibrillation. First approved in 2008.

Drug data last refreshed 18h ago

Mechanism of Action

Mechanism of Action Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.…

Indications (1)

atrial fibrillation

Clinical Trials (20)

NCT06672523Phase 1Recruiting

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Started Mar 2025

8 enrolled

Advanced Solid Tumors With Homozygous MTAP Deletion

NCT06360354Phase 1Recruiting

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Started May 2024

350 enrolled

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

NCT04892875Phase 1Withdrawn

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Started Dec 2023

Head and Neck CancerSquamous Cell Carcinoma of Head and NeckOral Cavity Squamous Cell Carcinoma+7 more

NCT05975073Phase 1/2Completed

A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Started Aug 2023

53 enrolled

MTAP-null Non-Small-Cell Lung CancerMTAP-null Solid Tumors

NCT05915442Phase 2Recruiting

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Started Jul 2023

23 enrolled

Oligometastatic Prostate Cancer

Worked on ADENOSINE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.